Allos Therapeutics, Inc. (Nasdaq:ALTH) today announced that the United States Patent and Trademark Office has issued a patent for the use of FOLOTYN™ (pralatrexate injection) for the treatment of T-cell lymphoma. U.S. Patent No. 7,622,470 was issued to Memorial-Sloan Kettering Cancer Center, SRI International and Southern Research Institute, and expires on November 24, 2025. Allos holds an exclusive worldwide license from these institutions to develop and market FOLOTYN for all indications.
“We are pleased to add this important patent to our intellectual property portfolio for FOLOTYN,” said Marc H. Graboyes, senior vice president, general counsel of Allos Therapeutics. “Patent protection is an essential component of our product life cycle management strategy, and this patent further strengthens the FOLOTYN franchise.”